Bethyl Laboratories
Mouse anti-PD-L1 Monoclonal Antibody [BLGM148]New
Primary
Catalog #A501-148
TargetPD-L1
HostMouse
CloneBLGM148
ReactivityHuman
ApplicationIHC
Image 1 of 1
local_shipping
This item has an estimated lead time of two weeks.
Product Description
PD-L1 is an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. PD-L1 is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma [taken from NCBI Entrez Gene (Gene ID: 55193)].
Specifications
Clonality
Monoclonal
Clone
BLGM148
Host
Mouse
Isotype
IgG1, kappa
Reactivity
Human
Format
Whole IgG
Conjugate Type
Unconjugated
Purity
Purified
Target Identity
TargetPD-L1
Antigen Species
Human
Gene ID29126
Gene Symbol
CD274
Gene Name
CD274 molecule
Uniprot IDQ9NZQ7
Protein Name
Programmed cell death 1 ligand 1
Alternate Names
Product Information
Applications
IHC
Buffer
Tris-buffered Saline with 1% BSA and <0.1% Sodium Azide
Storage Conditions
2 - 8 °C
Physical State
Liquid
Shelf Life
1 year from date of receipt
Country of Origin
USA
Applications
Immunohistochemistry (IHC)1:10 to 1:50
Documents
Product DatasheetPDF · A501-148 · Lot 1 (current lot)Open
Product DatasheetPDF · A501-148 · Lot 1 (current lot)Open
Safety Data SheetPDF · A501-148Open
Services
Antibody Conjugation
Antibody and conjugate formats developed together, built to your specification.
Request CustomizationCustom Monoclonal Antibody Discovery Services
Full custom monoclonal development, from immunization through validation.
Explore Monoclonal DevelopmentVHH Discovery
Single-domain antibodies for structurally difficult targets a conventional monoclonal can't reach.
Explore VHH DiscoveryResources
1



